Table 2.
Index Test | HCV Ab Status | # Studies (# Samples) | Sensitivity 95% CI | Specificity 95% CI | Positive LR 95% CI | Negative LR 95% CI |
---|---|---|---|---|---|---|
Abbott ARCHITECT1 | All | 23 (12,670) | 93.4%1 (90.1, 96.5) | 98.8%1 (97.4, 99.5) | 80.6 (36.4, 178.8) | 0.06 (0.04, 0.1) |
Abbott ARCHITECT2 | All | 33 (13,638) | 94.3%2 (92.8, 95.9) | ND | NA | NA |
Abbott ARCHITECT1 | Known Ab Positive | 16 (5,246) | 92.5%1 (86.9, 95.8) | 97.8%1 (94.7, 99.1) | 42 (16.4, 106.4) | 0.05 (0.03, 0.08) |
Abbott ARCHITECT2 | Known Ab positive | 27 (6,189) | 93.4%2 (91.4, 95.4) | ND | NA | NA |
Abbott ARCHITECT1 | Known Ab Negative | 5 (3,415) | 92.3%1 (3.7, 99.9) | 98.8%1 (97.3, 99.4) | 73.9 (32.6, 167.9) | 0.08 (0.004, 15.7)) |
Ortho ELISA-Ag1 | All | 5 (1,177) | 93.2%1 (81.6, 97.7) | 99.2%1 (87.9, 100) | 116.5 (6.7, 977) | 0.06 (0.02, 0.07) |
Ortho ELISA-Ag2 | All | 6 (1,423) | 90.8%2 (83.5, 98.2) | ND | NA | NA |
EIKEN Lumispot HCV Ag3 | All | 2 (235) | 97.5–98.1%3 | ND | NA | NA |
Fujirebio Lumipulse Ortho HCV Ag4 | All | 1 (80) | 95.0%4 (90.2, 99.8) | ND | NA | NA |
Hunan Jynda Bioengineering Group HCV Core Ag ELISA1 | All | 4 (562) | 59.5%1 (46.0, 71.7) | 82.9%1 (58.6, 94.3) | 3.5 (1.1, 12.6) | 0.28 (0.2, 0.3) |
HCV = Hepatitis C Virus, cAg = Core Antigen, Ab = Antibody, CI = Confidence Interval, LR = likelihood ratio, ELISA = enzyme linked immunosorbent assay, ND = no data, NA = Not applicable—if sensitivity and specificity results were not available from meta-analysis, likelihood ratios were not calculated.
Determined by bivariate meta-analysis – “metandi” command in STATA
Determined by univariate meta-analysis – “metan” command in STATA
Meta-analysis not possible, range of results seen across studies reported
Results from one study only